Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) (TA969)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 April 2024
Camlipixant for treating refractory or unexplained chronic cough [ID6722]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Isavuconazol for treating invasive aspergillosis or mucormycosis in people 1 to 17 years [TSID12284]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC